The Key Players in Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019.

Monday 10 August 2015, Amsterdam

The report recognizes the following companies as the key players in the Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market: GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co and Tesaro.

Other Prominent Vendors in the market are: Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, Otsuka Pharmaceutical, ProStrakan, Sandoz (Novartis), Solvay Pharmaceuticals, Specialised Therapeutics Australia, Sun Pharma, Taiho Pharmaceutical and Teva Pharmaceuticals.

Commenting on the report, an analyst said: “One major trend in the market is individuals tend to develop resistance to monotherapies over a period of time, resulting in the increased preference for combination therapies. These combination therapies have a better safety and efficacy profile, increasing their preference for treating CINV.”

According to the report, one key driver of this market is patent expiries result in the loss of market exclusivity of a drug, leading to a rapid decline in its sales. This leads to the market entry of generic forms that have a similar efficacy and safety profile as the branded drug and are available at low prices. The patents of most of the CINV drugs have either expired or are set to expire by the end of the forecast period.

Further, the report states that one of the major challenges in the market is off-label drugs are unapproved medications, but show efficacy in the treatment of the condition. Many off-label drugs are used to manage CINV. Corticosteroids, such as dexamethasone, are commonly used to treat CINV.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.